Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma

Sponsor
The First People's Hospital of Lianyungang
Study ID
NCT02848794
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • High-grade Glioma

Eligibility Criteria

Sex
ALL
Age
15 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib and Irinotecan — DRUG
    Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.

Study Details

The study is aimed to evaluate the efficacy and safety of Apatinib and Irinotecan in patients with recurrent high-grade glioma.

Key Dates

Start date
Jul 31, 2016
Status verified
Jun 2017
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib+Irinotecan
    Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: From enrollment to progression of disease. Estimated about 6 months ]

Central Contacts

Related Studies